Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHYF) Interest Expenses (2019 - 2025)

Historic Interest Expenses for Innate Pharma (IPHYF) over the last 7 years, with Q2 2025 value amounting to -$3.2 million.

  • Innate Pharma's Interest Expenses fell 4274.93% to -$3.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$11.6 million, marking a year-over-year decrease of 12110.33%. This contributed to the annual value of $4.2 million for FY2024, which is 11514.26% up from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Interest Expenses is -$3.2 million, which was down 4274.93% from -$4.2 million recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Interest Expenses peaked at -$5428.7 during Q4 2022, and registered a low of -$6.6 million during Q2 2022.
  • Over the past 5 years, Innate Pharma's median Interest Expenses value was -$2.7 million (recorded in 2024), while the average stood at -$3.0 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first surged by 9988.13% in 2022, then plummeted by 3626849.98% in 2023.
  • Innate Pharma's Interest Expenses (Quarter) stood at -$4.6 million in 2021, then surged by 99.88% to -$5428.7 in 2022, then plummeted by 36268.5% to -$2.0 million in 2023, then plummeted by 115.14% to -$4.2 million in 2024, then increased by 25.3% to -$3.2 million in 2025.
  • Its Interest Expenses stands at -$3.2 million for Q2 2025, versus -$4.2 million for Q4 2024 and -$2.2 million for Q2 2024.